Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy

Targeted Oncology

Volumn 11, Issue 2, 2016, Pages 183-195

  Papademetrio, Daniela Laura ^a,b   Lompardía, Silvina Laura ^a,b   Simunovich, Tania ^a   Costantino, Susana ^a,b   Mihalez, Cintia Yamila ^a,b   Cavaliere, Victoria ^a   Álvarez, Élida ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CAFFEIC ACID PHENETHYL ESTER; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC3 II PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; ANTINEOPLASTIC AGENT; CAFFEIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITRILE; PHENETHYL ALCOHOL; PROTEIN KINASE INHIBITOR;

ADENOCARCINOMA CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUNEL ASSAY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BUTADIENES; CAFFEIC ACIDS; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; NITRILES; PANCREATIC NEOPLASMS; PHENYLETHYL ALCOHOL; PROTEIN KINASE INHIBITORS; SURVIVAL RATE;

EID: 84941711244     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0388-3     Document Type: Article

References (65)

1. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–17
2. Hidalgo M (2012) New insights into pancreatic cancer biology. Ann Oncol 23(Suppl 10):135–8
3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29
4. O'Reilly KE, Rojo F, She QB et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–8
5. Garcia MG, Alaniz LD, Cordo Russo RI et al (2009) PI3K/Akt inhibition modulates multidrug resistance and activates NFkB in murine Lymphoma cell lines. Leuk Res 33:288–96
6. Cox AD, Der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1333(1):F51–71
7. Muerkoster S, Arlt A, Sipos B et al (2005) Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 65(4):1316–24
8. Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 40:139–46
9. De Luca A, Maiello MR, D'Alessio A et al (2012) The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16:S17–27
10. Shimizu T, Tolcher AW, Papadopoulos KP et al (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316–25
11. Wang LH (2014) LiY, Yang SN, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling. Br J Cancer 110(2):34–52
12. Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–75
13. Vaux DL, Silke J (2003) Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 304:499–504
14. Wei Y, Fan T, Yu M (2008) Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai) 40:278–88
15. Srinivasula SM, Ashwell JD (2008) IAPs: what's in a name? Mol Cell 30:123–35
16. Dubrez-Daloz L, Dupoux A, Cartier J (2008) IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7:1036–46
17. LaCasse EC, Mahoney DJ, Cheung HH et al (2008) IAP-targeted therapies for cancer. Oncogene 27:6252–75
18. Vucic D, Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13:5995–6000
19. Reggiori F, Klionsky DJ (2002) Autophagy in the eukaryotic cell. Eukaryot Cell 1(1):11–21
20. Shintani T, Klionsky DJ (2004) Autophagy in health and disease: a double-edged sword. Science 306(5698):990–5
21. Kirkegaard K, Taylor MP, Jackson WT (2004) Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol 2(4):301–14
22. Ogawa M, Yoshimori T, Suzuki T et al (2005) Escape of intracellular Shigella from autophagy. Science 307(5710):727–31
23. Hara T, Nakamura K, Matsui M et al (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441(7095):885–9
24. Komatsu M, Waguri S, Chiba T et al (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441(7095):880–4
25. Liang XH, Jackson S, Seaman M et al (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402(6762):672–6
26. Liang XH, Yu J, Brown K et al (2001) Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res 61(8):3443–9
27. Ravikumar B, Berger Z, Vacher C et al (2006) Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 15(7):1209–16
28. Papademetrio DL, Cavaliere V, Simunovich T et al (2014) Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. Target Oncol 9(2):123–34
29. Kabeya Y, Mizushima N, Ueno T et al (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19(21):5720–8
30. Rubinsztein DC, Cuervo AM, Ravikumar B et al (2009) In search of an "autophagomometer". Autophagy 5(5):585–9
31. Conroy T, Desseigne F, Ychou M et al (2001) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–25
32. Hill R, Rabb M, Madureira PA et al (2013) Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis 4:e791
33. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–6
34. Biankin AV, Waddell N, Kassahn KS et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399–405
35. Baines AT, Xu D, Der CJ (2011) Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 3:1787–808
36. Chen Z, Cheng K, Walton Z et al (2012) A murine lung cancer coclinical trial identifies genetic modifiers of therapeutic response. Nature 483(7391):613–7
37. Jänne PA, Shaw AT, Pereira JR et al (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38–47
38. McCubrey JA, Steelman LS, Chappell WH et al (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3:1068–111
39. Fujioka S, Sclabas GM, Schmidt C et al (2003) Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 9:346–54
40. Hu L, Shi Y, Hsu JH et al (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101:3126–35
41. Mayo MW, Wang CY, Cogswell PC et al (1997) Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812–5
42. Li L, Aggarwal BB, Shishodia S et al (2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101:2351–62
43. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203–8
44. Yamamoto Y, Gaynor RB (2001) Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 1:287–96
45. Aggarwal BB, Takada Y, Shishodia S et al (2004) Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 42:341–53
46. Karin M, Cao Y, Greten FR et al (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–10
47. Garg A, Aggarwal BB (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16:1053–68
48. Lin Y, Shi R, Wang X et al (2008) Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8:634–46
49. Cai X, Lu W, Yang Y et al (2013) Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNFα through downregulation of expression of nuclear factor κB-regulated gene products in human pancreatic cancer cells. PLoS One 8(10):e77126
50. Cavaliere V, Papademetrio DL, Lorenzetti M et al (2009) Caffeic Acid Phenylethyl Ester and MG-132 have apoptotic and antiproliferative effects on Leukemic cells but not on normal mononuclear cells. Transl Oncol 2(1):46–58
51. Velculescu VE (1999) Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes SAGE and its use in global gene expression analysis. Science 286(5444):1491–2
52. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8(1):61–70
53. Sarela AI, Macadam RC, Farmery SM et al (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46(5):645–50
54. Monzo M, Rosell R, Felip E et al (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17(7):2100–4
55. Shariat SF, Lotan Y, Saboorian H et al (2004) Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100(4):751–7
56. Tanaka K, Iwamoto S, Gon G et al (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Can 6(1):127–34
57. Jourdan M, Reme T, Goldschmidt H et al (2009) Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol 145(1):45–58
58. Cheng SM, Chang YC, Liu CY et al (2015) YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol 172(1):214–34
59. Wang J, Whiteman MW, Lian H et al (2009) A Non-canonical MEK/ERK Signaling Pathway Regulates Autophagy via Regulating Beclin 1. J Biol Chem 284(32):21412–24
60. Pattingre S, Bauvy C, Codogno PZ (2003) Amino acids interfere with the ERK1⁄ 2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J Biol Chem 278:16667–74
61. Ellington AA, Berhow MA, Singletary KW (2006) Inhibition of Akt signaling and enhanced ERK1⁄ 2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis 27:298–306
62. Copetti T, Demarchi F, Schneider C (2009) p65/RelA binds and activates the beclin 1 promoter. Autophagy 5(6):858–9
63. Vadlamudi RK, Shin J (1998) Genomic structure and promoter analysis of the p62 gene encoding a nonproteasomal multiubiquitin chain binding protein. FEBS Lett 435:138–42
64. David A (2014) An autophagic switch in the response of tumor cells to radiation and chemotherapy. Biochem Pharmacol 90:208–11
65. Yang S, Wang X, Contino G et al (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25(7):717–29